TY - JOUR
T1 - Reduction of subacute stent thrombosis (SAT) using heparin-coated stents in a large-scale, "real world" registry
AU - Gupta, Vishal
AU - Aravamuthan, Bhooma R.
AU - Baskerville, Susan
AU - Smith, Susan K.
AU - Gupta, Vijaya
AU - Lauer, Michael A.
AU - Fischell, Tim A.
PY - 2004/6/1
Y1 - 2004/6/1
N2 - Purpose. This study was designed to compare the rates of subacute stent thrombosis (SAT) among patients receiving heparin-coated stents to patients receiving bare-metal stents in real world, contemporary coronary interventions. Background. Controlled trials with heparin-coated coronary stents have shown a trend toward decreased rates of SAT. Methods and Results. The data in this study were collected from a single, large cardiac center over a period of 9 months. All patients who underwent coronary stent implantation during this 9-month period were included in the study (1,288 patients; 1,366 procedures; 2,231 stents). All patients were treated with aspirin and clopidogrel (or tidopidine) after stenting. Primary thrombotic outcome was defined as angiographically documented SAT and/or sudden unexplained cardiac death (SCD) within 30 days of the procedure. Follow-up data (1,264/1,276 patients) were obtained in 99% of patients. A total of 337 patients received 543 heparin-coated stents (BX Velocity™ Hepacoat™) and 939 patients received bare-metal stents (1,688 stents). SAT was seen in 25/1,024 procedures (2.44%) in the bare-metal stent group and 1/342 procedures (0.29%) in the heparin-coated stent group. Primary thrombotic outcomes (SAT or SCD) were observed in 31/1,024 procedures (3.03%) in the bare-metal stent cohort and in 2/342 procedures (0.58%) in the heparin-coated stent group. The vast majority (96%) of the patients who had SAT within 30 days had initial stent placement for an acute coronary syndrome (p < 0.0001). Conclusion. This large, single-center registry demonstrates a significant reduction of SAT using heparin-coated stents compared to bare-metal stents in real world coronary interventions.
AB - Purpose. This study was designed to compare the rates of subacute stent thrombosis (SAT) among patients receiving heparin-coated stents to patients receiving bare-metal stents in real world, contemporary coronary interventions. Background. Controlled trials with heparin-coated coronary stents have shown a trend toward decreased rates of SAT. Methods and Results. The data in this study were collected from a single, large cardiac center over a period of 9 months. All patients who underwent coronary stent implantation during this 9-month period were included in the study (1,288 patients; 1,366 procedures; 2,231 stents). All patients were treated with aspirin and clopidogrel (or tidopidine) after stenting. Primary thrombotic outcome was defined as angiographically documented SAT and/or sudden unexplained cardiac death (SCD) within 30 days of the procedure. Follow-up data (1,264/1,276 patients) were obtained in 99% of patients. A total of 337 patients received 543 heparin-coated stents (BX Velocity™ Hepacoat™) and 939 patients received bare-metal stents (1,688 stents). SAT was seen in 25/1,024 procedures (2.44%) in the bare-metal stent group and 1/342 procedures (0.29%) in the heparin-coated stent group. Primary thrombotic outcomes (SAT or SCD) were observed in 31/1,024 procedures (3.03%) in the bare-metal stent cohort and in 2/342 procedures (0.58%) in the heparin-coated stent group. The vast majority (96%) of the patients who had SAT within 30 days had initial stent placement for an acute coronary syndrome (p < 0.0001). Conclusion. This large, single-center registry demonstrates a significant reduction of SAT using heparin-coated stents compared to bare-metal stents in real world coronary interventions.
KW - Angioplasty
KW - Biocompatible
KW - Blood vessel prosthesis implantation
KW - Coated materials
KW - Complications
KW - Percutaneous transluminal coronary intervention
UR - http://www.scopus.com/inward/record.url?scp=2642558698&partnerID=8YFLogxK
M3 - Article
C2 - 15155999
AN - SCOPUS:2642558698
SN - 1042-3931
VL - 16
SP - 304
EP - 310
JO - Journal of Invasive Cardiology
JF - Journal of Invasive Cardiology
IS - 6
ER -